Foresite Capital Management IV’s Cytokinetics CYTK Stock Holding History

Foresite Capital Management IV’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$33.2M	Buy	503,295 +45,000	+10%	+$2.86M	13.99%	2
2025 Q4	$29.1M	Hold	458,295	–	–	12.68%	2
2025 Q3	$25.2M	Buy	+458,295	New	+$18.9M	13.79%	2
2021 Q3	–	Sell	-545,101	Closed	-$10.8M	–	13
2021 Q2	$10.8M	Sell	545,101 -336,800	-38%	-$7.91M	1.46%	9
2021 Q1	$20.5M	Sell	881,901 -554,091	-39%	-$11.8M	2.46%	9
2020 Q4	$29.8M	Sell	1,435,992 -236,300	-14%	-$4.32M	3.24%	8
2020 Q3	$36.2M	Buy	1,672,292 +65,000	+4%	+$1.52M	8.16%	6
2020 Q2	$37.9M	Sell	1,607,292 -570,000	-26%	-$10.7M	18.45%	2
2020 Q1	$25.7M	Sell	2,177,292 -221,678	-9%	-$2.83M	31.64%	1
2019 Q4	$25.5M	Buy	2,398,970 +500,000	+26%	+$5.14M	10.98%	4
2019 Q3	$21.6M	Hold	1,898,970	–	–	6.98%	6
2019 Q2	$21.4M	Buy	1,898,970 +175,800	+10%	+$1.7M	6.04%	5
2019 Q1	$13.9M	Buy	1,723,170 +1,548,022	+884%	+$11.4M	5.01%	9
2018 Q4	$1.11M	Buy	+175,148	New	+$1.28M	0.51%	18

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Foresite Capital Management IV's CYTK Position: Q1 2026 in Review

Foresite Capital Management IV increased its Cytokinetics (CYTK) stake by 9.8% in Q1 2026, buying an estimated $2.86M and bringing the position to 503,295 shares worth $33.2M. The position accounts for 13.99% of the portfolio, ranked #2.

Foresite Capital Management IV first reported a position in CYTK in Q4 2018 and has held it in 14 quarters since. The position peaked at $37.9M in Q2 2020. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Foresite Capital Management IV held 503,295 shares of Cytokinetics worth $33.2M as of Q1 2026.
Foresite Capital Management IV bought 45,000 Cytokinetics shares in Q1 2026, an estimated $2.86M.
Cytokinetics made up 13.99% of Foresite Capital Management IV's portfolio in Q1 2026, its #2 holding.
Foresite Capital Management IV first reported a position in Cytokinetics in Q4 2018 and has held it in 14 quarters since.
Foresite Capital Management IV's Cytokinetics position peaked at $37.9M in Q2 2020.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Foresite Capital Management IV's 13F filing for Q1 2026, filed 15 May 2026.